Background:
Alzheimer’s Disease (AD) is still a great global challenge and agents with various mechanisms represent a promising therapeutic opportunity. Theracurmin, a very highly absorbable curcumin formulation, was shown to improve memory and attention in non-demented people.
Objective:
To investigate the effect of Theracurmin on disease course in elderly patients with mild cognitive impairment (MCI) and AD.
Methods:
This follow-up study was performed retrospectively on 93 patients with MCI or AD. All patients underwent comprehensive geriatric assessment, including Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), clock-drawing test, activities of daily living (ADL), at baseline and end of the 6th-month. 19 patients with AD and 17 with MCI were treated with Theracurmin 180 mg/day per oral.
Results:
MMSE, MOCA and instrumental ADL scores decreased in AD patients that were not treated with Theracurmin (p<0.001, p=0.011, and p=0.004, respectively), whereas these scores remained stable in those treated with Theracurmin. This stabilization in the instrumental ADL was also observed in MCI patients treated with Theracurmin. During the follow-up, three of MCI patients who did not receive Theracurmin progressed to AD, whereas only one patient progressed in those who received it.
Conclusion:
Theracurmin seems to be a therapeutic option for elderly patients with AD and MCI via providing stabilization of the disease course by preventing progressive loss in cognitive functions and ADLs.
Soy Lecithin-Derived Phosphatidylserine Plus Phosphatidic Acid: Effects on Brain Functions in Elderly Patients with Alzheimer's Disease and Dementia
